# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-096193
Filing Date
2024-08-13
Accepted
2024-08-13 16:08:44
Documents
63
Period of Report
2024-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | achv-20240630.htm iXBRL | 10-Q | 1986770
2 | EX-31.1 | achv-ex31_1.htm | EX-31.1 | 10497
3 | EX-32.1 | achv-ex32_1.htm | EX-32.1 | 5867
| Complete submission text file | 0000950170-24-096193.txt |  | 8051294

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
4 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | achv-20240630.xsd | EX-101.SCH | 1277093
66 | EXTRACTED XBRL INSTANCE DOCUMENT | achv-20240630_htm.xml | XML | 1293117

Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 033-80623 | Film No.: 241201459
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)